Amniotics

Less than 1K followers

Amniotics develops and manufactures stem cell therapies in our own GMP certified facility. Amniotics was born out of the discovery of a novel source of stem cells in full-term amniotic fluid. Based on a decade of research at the internationally recognized Lund University Stem Cell Center and Hospital, the company is pioneering the harvesting and propagation of tissue-specific neonatal quality mesenchymal stem cells (MSC). The company is listed at Nasdaq First North Growth Market in Stockholm.

All

Research

Press releases

3rd party

ShowingAll content types

Regulatory press release9/23/2024, 11:30 AM

The Swedish Companies Registration Office has authorised the implementation of the merger plan between Magle group and Amniotics

Regulatory press release9/23/2024, 11:30 AM

Bolagsverket har lämnat tillstånd att verkställa fusionsplanen mellan Magle group och Amniotics

Press release8/20/2024, 11:27 AM

Redeye: Amniotics H1 2024 - Merger with Magle

Join Inderes community

Research, tools and community to support better investment decisions.

Inderes account

Follow companies and get notifications on the ones you track

Analysts' recommendations and comments

Stock comparison tool and other popular tools

Regulatory press release8/20/2024, 6:45 AM

Amniotics AB (publ) Rapport över det första halvåret 2024

Regulatory press release8/6/2024, 8:45 AM

Amniotics receives conditional approval to delist from Nasdaq First North Growth Market

Regulatory press release8/6/2024, 8:45 AM

Amniotics erhåller villkorat godkännande om avnotering från Nasdaq First North Growth Market

Regulatory press release8/6/2024, 6:45 AM

Amniotics applies for delisting from Nasdaq First North Growth Market conditional upon completion of the merger with Magle Group

Regulatory press release8/6/2024, 6:45 AM

Amniotics ansöker om avnotering från Nasdaq First North Growth Market villkorat av slutförande av fusionen med Magle Group

Regulatory press release7/15/2024, 11:45 AM

Kommuniké från extra bolagsstämma i Amniotics AB (publ) den 15 juli 2024

Regulatory press release7/1/2024, 3:30 PM

Amniotics publishes merger document regarding the merger with Magle Group

Regulatory press release7/1/2024, 3:30 PM

Amniotics offentliggör fusionsdokument avseende fusionen med Magle Group

Regulatory press release6/28/2024, 12:30 PM

Kommuniké från årsstämma i Amniotics AB (publ) den 28 juni 2024

Regulatory press release6/12/2024, 9:00 AM

Kallelse till extra bolagsstämma i Amniotics AB (publ)

Regulatory press release5/30/2024, 6:05 PM

Statement from the Board of Directors of Amniotics regarding the merger with Magle Group

Regulatory press release5/30/2024, 6:05 PM

Uttalande från styrelsen i Amniotics med anledning av fusionen med Magle Group

Regulatory press release5/30/2024, 6:00 PM

Magle Group and Amniotics merge to create a leader in high-quality life-changing healthcare innovations with a broadened CDMO offering

Regulatory press release5/30/2024, 6:00 PM

Magle Group och Amniotics går samman och skapar en ledande aktör inom högkvalitativa, livsförändrande hälsoinnovationer med ett breddat CDMO-erbjudande

Regulatory press release5/28/2024, 10:40 AM

Kallelse till årsstämma i Amniotics AB (publ)

Regulatory press release5/28/2024, 6:55 AM

Amniotics årsredovisning 2023 publicerad

Regulatory press release5/21/2024, 7:50 PM

Amniotics secures continued short-term capital needs by extending loan agreement and continued services under service agreement

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.